Potassium Channel Activation and Arrhythmogenicity

  • Michiel J. Janse
  • Arthur A. M. Wilde
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 179)

Abstract

It may be expected that potassium channel openers (KCOs), in particular openers of the ATP sensitive K+ channel, will become increasingly available for the treatment of angina pectoris and hypertension. It is therefore important to define possible proarrhythmic effects of KCOs especially in the setting of acute ischemia. As will be shown there are surprisingly few experimental data allowing a firm conclusion be made regarding this important issue. A discussion about pro- and anti-arrhythmic effects of KCOs is confounded by a number of factors, of which the most important are: dosage, species differences, experimental models (notably in vivo experiments versus experiments on isolated preparations or myocytes), heart rate, and in the setting of ischaemia the time after coronary artery occlusion. We will firstly discuss the effects of KCOs on normoxic cardiac tissue before focusing on ischaemia-induced arrhythmias.

Keywords

Ischemia Catecholamine Cardiol Glycoside Arena 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988;62:395–410.PubMedGoogle Scholar
  2. [2]
    Coussaye JE de la, Eledjam JJ, Bruelle P et al. Electrophysiologic and arrhythmogenic effects of the potassium channel agonist BRL 38227 in anesthetized dogs. J Cardiovasc Pharmacol 1993;22:722–30.CrossRefGoogle Scholar
  3. [3]
    Spinelli W, Follmer C, Parsons R, Colatsky T. Effects of cromakalim, pinacidil and nicorandil on cardiac refractoriness and arterial pressure in open chest dogs. Eur J Pharmacol 1990;179:243–52.PubMedCrossRefGoogle Scholar
  4. [4]
    Kojima S, Ishikawa S, Ohsawa K, Mori H. Determination of effective and safe dose for intracoronary administration of nicorandil in dogs. Cardiovasc Res 1990;24:727–32.PubMedCrossRefGoogle Scholar
  5. [5]
    Bazil MK, Ukropec JA, Williams PD. Hemodynamic and electrocardiographic (ECG) effects of CL 188,294, a potassium channel opener, in conscious dogs (abstract). Pharmacologist 1993,35:178.Google Scholar
  6. [6]
    Padrini R, Bova S, Cargnelli G et al. Effects of pinacidil on guinea-pig isolated perfused heart with particular reference to the pro-arrhythmic effect. Br J Pharmacol 1992;105:715–9.PubMedGoogle Scholar
  7. [7]
    Frydman AM, Chapelle Ph, Diekmann HW et al. Pharmacokinetics of nicorandil. Am J Cardiol 1989;63 (Supp J):25J-33J.PubMedCrossRefGoogle Scholar
  8. [8]
    Friedel HA, Brogden RV. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 1990;39:929–67.PubMedCrossRefGoogle Scholar
  9. [9]
    Hakayama K, Fan Z, Marumo F et al. Action of nicorandil on ATP-sensitive K+ channel in guinea pig ventricular myocytes. Br J Pharmacol 1991,103: 1641–8.Google Scholar
  10. [10]
    Arena JP, Kass RS. Enhancement of potassium-sensitive current in heart cells by pinacidil. Circ Res 1989;65:436–45.PubMedGoogle Scholar
  11. [11]
    Nakayama K, Fan Z, Maruno F, Hiraoka M. Interrelation between pinacidil and intracellular ATP-sensitive K+ current in guinea pig ventricular myocytes. Circ Res 1990;67:1124–33.PubMedGoogle Scholar
  12. [12]
    Imanishi S, Arita M, Aomine M, Kiyosue T. Antiarrhythmic effects of nicorandil on canine cardiac Purkinje fibers. J Cardiovasc Pharmacol 1984; 6:772–9.PubMedCrossRefGoogle Scholar
  13. [13]
    De Diego JM, Antzelevitch C. Pinacidil-included electrical heterogeneity and extrasystolic activity in canine ventricular tissue. Circulation 1993; 88:1177–89.PubMedGoogle Scholar
  14. [14]
    Goldberg MR. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channel. J Cardiovasc Pharmacol 1988;12(Suppl 2):S41-S47.PubMedCrossRefGoogle Scholar
  15. [15]
    Nony P. Girard P, Arnand P et al. Electrophysiologic effects of a potassium channel activator (pinacidil) on repolarization parameters in healthy volunteers: a surface ECG study. J Cardiovasc Pharmacol 1993;22:534–9.PubMedCrossRefGoogle Scholar
  16. [16]
    Krumenacker M, Roland E. Clinical profile of nicorandil, an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992;20 (Suppl III):S94-S102.Google Scholar
  17. [17]
    Liu B, Golyan F, McCullough JR, Vassalle M. Electrophysiological and antiarrhythmic effect of the K-channel opener, BRL 34915, in cardiac Purkinje fibers. Drug Dev Res 1988;14:123–39.CrossRefGoogle Scholar
  18. [18]
    Lathrop DA, Nanasi PP, Varro A. In vitro cardiac models of dog Purkinje fibre triggered and spontaneous electrical activity: effects of nicorandil. Br J Pharmacol 1990;99:114–23.Google Scholar
  19. [19]
    Spinelli W, Sorota S, Siegal M, Hoffman BF. Antiarrhythmic actions of the ATP-regulated K+ current activated by pinacidil. Circ Res 1991;68:1127–37.PubMedGoogle Scholar
  20. [20]
    Gotanda K, Satoh K, Taira N. Is the cardiovascular profile of BRL 34915 characteristic of potassium channel activators? J Cardiovasc Pharmacol 1998;12:239–46.CrossRefGoogle Scholar
  21. [21]a
    Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their action on arrhythmogenic mechanisms. Circulation 1991;84:1831–51,Google Scholar
  22. [21]b
    Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their action on arrhythmogenic mechanisms. Eur Heart J 1991;12:1112–31.Google Scholar
  23. [22]
    Members of the Sicilian Gambit. Antiarrhythmic Therapy: a pathophysiological approach. Armonk NY: Futura Publishing Company Inc, 1994.Google Scholar
  24. [23]
    Kerr MJ, Wilson R, Shanks RG. Suppression of ventricular arrhythmias after coronaiy artery ligation by pinacidil, a vasodilator drug. J Cardiovasc Pharmacol 1985;7:875–83.PubMedCrossRefGoogle Scholar
  25. [24]
    Komori S, Ishii M, Hashimoto K. Antiarrhythmic effects of coronary vasodilators on canine ventricular arrhythmia models. Jpn J Pharmacol 1985;38:73–82.PubMedCrossRefGoogle Scholar
  26. [25]
    Hashimoto K, Haruno A, Matsuzaki T et al. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectivenss? Cardiovasc Drugs Ther 1991;5:805–18.PubMedCrossRefGoogle Scholar
  27. [26]
    Fish FA, Prakash C, Roden DM. Suppression of repolarization related arrhythmias in vitro and in vivo by low-dose potassium channel activator. Circulation 1990;82:1362–9.PubMedCrossRefGoogle Scholar
  28. [27]
    Takahashi N, Ito M, Saikawa T, Arita M. Nicorandil suppressess early aflerdepolarizations and ventricular arrhythmias induced by ceasium chloride in rabbits in vivo. Cardiovasc Res 1991;25:445–452.PubMedCrossRefGoogle Scholar
  29. [28]
    Vos MA, de Groot M, Lipcsei GE et al. Lemakalim demonstrates mechanism of specific antiarrhythmic properties without proarrhythmogenity (abstract). Circulation 1992;86(Suppl I):I-560.Google Scholar
  30. [29]
    Carlsson L, Abrahamsson C, Drews L, Duker G. Antiarrhythmic effect of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation 1992;85:1491–500.PubMedGoogle Scholar
  31. [30]
    D’Alonzo AJ, Hess TA, Darbenzio RB, Sewter JC. Effects of intracoronary cromakalim, pinacidil, or diltiazem on cesium-chloride-induced arrhythmias in anesthetized dogs under conditions of controlled coronary blood flow. J Cardiovasc Pharmacol 1993;21:677–83.PubMedCrossRefGoogle Scholar
  32. [31]
    Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049–169.PubMedGoogle Scholar
  33. [32]
    Wit AL, Janse MJ. The ventricular arrhythmias of ischemia and infarction. Electrophysiological mechanisms. Mount Kisco NY, Futura Publishing Company Inc, 1993.Google Scholar
  34. [33]
    Daugherty A, Frayne KN, Redfern WS, Woodward B. The role of catecholamines in the production of ischemia-induced ventricular arrhythmias in the rat in vivo and in vitro. Br J Pharmacol 1986;87:265–77.PubMedGoogle Scholar
  35. [34]
    Penny WJ. The deleterious effects of myocardial catecholamines on cellular electrophysiology and arrhythmias during ischemia and reperfusion. Eur Heart J 1984;5:960–73.PubMedGoogle Scholar
  36. [35]
    Corr PB, Witkowski FX, Sobel BE. Mechanisms contributing to malignant arrhythmias induced by ischemia in the cat. J Clin Invest 1978;61:109–119.PubMedCrossRefGoogle Scholar
  37. [36]
    Cotor SJ. Anesthetized rabbit as a model for ischemia- and reperfusion-induced arrhythmias. J Pharmacol Methods 1989;21:263–79.CrossRefGoogle Scholar
  38. [37]
    Coronel R, Wilms-Schopman FJG, Dekker LRC, Janse, MJ. Heterogeneities in [K+]o and TQ potential, and the inducibility by ventricular fibrillation during acute regional ischemia in the isolated perfused porcine heart. Circulation 1995 (in press).Google Scholar
  39. [38]
    Wilde AAM. Role of ATP-sensitive K+ channel current in ischemic arrhythmias. Cardiovasc Drugs Ther 1993;7:521–6.PubMedCrossRefGoogle Scholar
  40. [39]
    Mitani A, Kinoshita K, Fukamachi K et al. Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusioa Am J Physiol 1991;261:H1864-H71.PubMedGoogle Scholar
  41. [40]
    Venkatesh N, Stuart JS, Lamp ST, Alexander LD, Weiss JN. Activation of ATP-sensitive K+ channels by cromakalim. Effects of cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle. Circ Res 1992;71:1324–33.PubMedGoogle Scholar
  42. [41]
    Vanheel B, de Hemptinne A. Influence of KAtp channel modulation on net potassium efflux from ischaemic mammalian cardiac tissue. Cardiovasc Res 1992;26:1030–9.PubMedCrossRefGoogle Scholar
  43. [42]
    Wilde AAM, Aksnes, G. Myocardial potassium loss and cell depolarisation in ischaemia and hypoxia. Cardiovasc res 1995;29:1–15.PubMedGoogle Scholar
  44. [43]
    Martin CL, Chinn K. Pinacidil opens ATP-dependent K+ channels in an ATP- and temperature-dependent manner. J Cardiovasc Pharmacol 1990;15:510–4.PubMedCrossRefGoogle Scholar
  45. [44]
    Cole WC, McPherson CD, Sontag D. ATP regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571–81.PubMedGoogle Scholar
  46. [45]
    Wilde AAM, Schumacher CA, Fiolet JWT et al. Opening of ATP-sensitive potassium channel does not necessarily contribute to potassium accumulation in the globally ischemic rabbit heart (abstract). J Mol Cell Cardiol 1992;24:S276.CrossRefGoogle Scholar
  47. [46]
    Tan HL, Mazón P, Veiberne HJ et al. Ischaemic preconditioning delays ischaemia-induced cellular uncoupling by activation of ATP sensitive potassium channels. Cardiovasc Res 1993;27:644–51.PubMedCrossRefGoogle Scholar
  48. [47]
    D’Alonzo AJ, Daibenzio RB, Parham CS, Grover GJ. Effects of intracoronary cromakalim on postischaemic contractile fonction and action potential duration. Cardiovasc Res 1992;26:1046–53.PubMedCrossRefGoogle Scholar
  49. [48]
    Meesmann W. Early arrhythmias and primaiy ventricular fibrillation after acute myocardial ischaemia in relation to pre-existing coronary collaterals. In: Early arrhythmias resulting from myocardial ischaemia. Mechanisms and prevention by drugs. JR Parratt (ed), London, MacMillan, 1982; 93–112.Google Scholar
  50. [49]
    Trolese-Mongheal Y, Duchene-Marullaz P, Trolese JF et al. Sudden death and experimental acute myocardial infarction. Am J Cardiol 1985;56:677–81.PubMedCrossRefGoogle Scholar
  51. [50]
    Chi L, Uprichard ACG, Lucchesi BR. Profibrillatoiy actions of pinacidil in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol 1990;15:452–64.PubMedCrossRefGoogle Scholar
  52. [51]
    Kitzen JM, McCallum JD, Harvey C et al. Potassium channel activators cromakalim and celikalim (WAY-120,491) fail to decrease myocardial infarct size in the anesthetized canine. Pharmacology 1992;45:71–82.PubMedCrossRefGoogle Scholar
  53. [52]
    Grover GJ, Dzwonczyk S, Parham CS, Sleph PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drugs Ther 1990;4:465–74.PubMedCrossRefGoogle Scholar
  54. [53]
    D’Alonzo AJ, Hess TA, Darbenzio RB et al. Effects of cromakalim or pinacidil on pacing- and ischaemia-induced ventricular fibrillation in the anesthetized pig. Basic Res Cardiol 1994;89:162–76.Google Scholar
  55. [54]
    Smith WT, Fleet WF, Johnson TA, Cascio WE. The I-B phase of ventricular arrhythmias in ischemic in situ porcine heart is related to changes in cell-to-cell electrical coupling (abstract). Circulation 1994;90:I–524.Google Scholar
  56. [55]
    Wolleben CD, Sanguineus MC, Siegl PKS. Influence of ATP-sensitive potassium modulators on ischemia-induced fibrillation in isolated rat hearts. J Mol Cell Cardiol 1989;21:783–788.PubMedCrossRefGoogle Scholar
  57. [56]
    Lu H, Remeysen O, De Clerc F. The protection by ischemic preconditioning against myocardial ischemia- and reperfusion-induced arrhythmias is not mediated by ATP-sensitive potassium channels in the rat. Cor Art Dis 1993;4:649–57.CrossRefGoogle Scholar
  58. [57]
    D’Alonzo AJ, Darbenzio RB, Hess TA et al. Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia. Cardiovasc Res 1994;28:881–7.PubMedCrossRefGoogle Scholar
  59. [58]
    Yao Z, Gross GJ. Effects of the Katp channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769–75.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Michiel J. Janse
    • 1
  • Arthur A. M. Wilde
    • 1
  1. 1.Department of Experimental & Clinical Cardiology, M-0-52, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations